Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | SR-II-138A | CTRPv2 | pan-cancer | AAC | 0.011 | 0.7 |
mRNA | BRD4132 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |
mRNA | myricetin | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |
mRNA | SZ4TA2 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.7 |
mRNA | BRD-K71935468 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |
mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.019 | 0.7 |
mRNA | PD-0332991 | CCLE | pan-cancer | AAC | 0.017 | 0.7 |
mRNA | BRD-K51490254 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.7 |
mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.011 | 0.7 |
mRNA | NVP-BEZ235 | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |